| Literature DB >> 28679655 |
Douglas Sipp1,2,3,4, Timothy Caulfield5,5, Jane Kaye6, Jan Barfoot7, Clare Blackburn7, Sarah Chan8, Michele De Luca9, Alastair Kent10, Christopher McCabe11, Megan Munsie12,13, Margaret Sleeboom-Faulkner14, Jeremy Sugarman15, Esther van Zimmeren16, Amy Zarzeczny17, John E J Rasko18,19,20.
Abstract
Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.Entities:
Mesh：
Year: 2017 PMID： 28679655 DOI： 10.1126/scitranslmed.aag0426
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956